市場調査レポート

商品コード

1193200

多汗症治療市場：タイプ別、治療別、年齢別：世界の機会分析および産業予測、2021-2031年

Hyperhidrosis Treatment Market By Type, By Treatment, By Age : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年10月01日 | 発行: Allied Market Research

| ページ情報: 英文 281 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

多汗症治療の世界市場は2021年に5億7530万米ドルとなり、2031年には9億5070万米ドルに達し、2022年から2031年にかけてCAGR5.1％で成長すると推定されます。

多汗症の人は、過剰で予測不可能な発汗を経験します。多汗症の人は、涼しい場所や安静にしているときでも汗をかくことがあります。多汗症の人は、体の汗腺が過剰に反応します。過度の発汗は、健康問題や感情（不安など）によって引き起こされることもあります。多汗症の症状をコントロールすることは、多くの人々にとって絶え間ない闘いです。多汗症の患者さんは、汗腺が過剰に活性化しているようです。コントロールできない発汗は、身体的・精神的に深刻な苦痛をもたらすことがあります。多汗症の原因は特定されておらず、一般的には、発汗を調節する神経系の部分に障害が生じた結果であると考えられています。多汗症の症状が生活に与える影響は、その重篤度によって大きく異なる可能性があります。

多汗症治療市場の成長を牽引する主な要因は、多汗症の発症率の上昇、製品の上市・承認の急増であり、多汗症治療市場の成長要因として挙げられています。また、局所治療の利用が急増していることも市場の重要な傾向であり、予測期間中の市場成長に拍車をかけると予想されます。多汗症の発症率が大幅に上昇していることも、市場成長の主要な要因の1つとなっています。米国では、2％から5％の人が多汗症であると推定されており、このような高い症例数は、多汗症の治療手順を後押しすると期待されています。

概要
- 市場規模および予測
腋窩多汗症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
手掌多汗症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
足底多汗症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章多汗症治療市場：治療別

概要
- 市場規模および予測
ボツリヌス毒素注射
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
局所治療
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
経口治療薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
- 内服薬別多汗症治療市場：タイプ別
  - 抗コリン剤市場規模・予測：地域別
  - その他市場規模・予測：地域別

第6章多汗症治療市場：年齢別

概要
- 市場規模・予測
50歳以下
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
50歳以上
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章多汗症治療市場：地域別

概要
- 市場規模・予測
北米
- 主な動向と機会
- 北米市場規模・予測：タイプ別
- 北米市場規模・予測：治療別
  - 北米の内服薬別多汗症治療市場：タイプ別
- 北米市場規模・予測：年齢別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州の市場規模・予測：タイプ別
- 欧州の市場規模・予測：治療別
  - 欧州の内服薬別多汗症治療市場：タイプ別
- 欧州市場規模・予測：年齢別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：タイプ別
- アジア太平洋地域の市場規模・予測：治療別
  - アジア太平洋地域の内服薬別多汗症治療市場：タイプ別
- アジア太平洋地域の市場規模・予測：年齢別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：タイプ別
- LAMEAの市場規模・予測：治療別
  - LAMEAの内服薬別多汗症治療市場：タイプ別
- LAMEAの市場規模・予測：年齢別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ
  - LAMEAのその他の地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

AbbVie Inc.
Avanor Healthcare Ltd
Brickbell Biotech, Inc
Dr August Wolff Gmbh & Co. Kg Drugs
Eirion Therapeutics, Inc
Eli Lilly and Company
Hugel, Inc
Kaken Pharmaceutical Co., Ltd.
Roivant Sciences Ltd.
Theravida, Inc
Dr. Reddy's Laboratories Ltd.
Intas Pharmaceuticals Ltd

図表

LIST OF TABLES

TABLE 1. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. HYPERHIDROSIS TREATMENT MARKET, FOR AXILLARY HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. HYPERHIDROSIS TREATMENT MARKET FOR AXILLARY HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. HYPERHIDROSIS TREATMENT MARKET, FOR PALMAR HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. HYPERHIDROSIS TREATMENT MARKET FOR PALMAR HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. HYPERHIDROSIS TREATMENT MARKET, FOR PLANTAR HYPERHIDROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. HYPERHIDROSIS TREATMENT MARKET FOR PLANTAR HYPERHIDROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. HYPERHIDROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. HYPERHIDROSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 11. HYPERHIDROSIS TREATMENT MARKET, FOR BOTULINUM TOXIN INJECTIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. HYPERHIDROSIS TREATMENT MARKET FOR BOTULINUM TOXIN INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. HYPERHIDROSIS TREATMENT MARKET, FOR TOPICAL TREATMENT, BY REGION, 2021-2031 ($MILLION)
TABLE 14. HYPERHIDROSIS TREATMENT MARKET FOR TOPICAL TREATMENT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. HYPERHIDROSIS TREATMENT MARKET, FOR ORAL MEDICATION, BY REGION, 2021-2031 ($MILLION)
TABLE 16. HYPERHIDROSIS TREATMENT MARKET FOR ORAL MEDICATION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. GLOBAL ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 18. HYPERHIDROSIS TREATMENT MARKET, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 19. HYPERHIDROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. GLOBAL HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 21. HYPERHIDROSIS TREATMENT MARKET, FOR BELOW 50 YEARS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. HYPERHIDROSIS TREATMENT MARKET FOR BELOW 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. HYPERHIDROSIS TREATMENT MARKET, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 ($MILLION)
TABLE 24. HYPERHIDROSIS TREATMENT MARKET FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. HYPERHIDROSIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 32. U.S. HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 33. U.S. HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 34. CANADA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 35. CANADA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 36. CANADA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 37. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 38. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 39. MEXICO HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 40. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 41. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 42. EUROPE ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 43. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 44. EUROPE HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 45. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 46. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 47. GERMANY HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 48. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 49. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 50. FRANCE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 51. UK HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 52. UK HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 53. UK HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 54. ITALY HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 55. ITALY HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 56. ITALY HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 57. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 58. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 59. SPAIN HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 68. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 70. JAPAN HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 71. CHINA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. CHINA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 73. CHINA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 74. INDIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 75. INDIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 76. INDIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 86. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 87. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 88. LAMEA ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 89. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 90. LAMEA HYPERHIDROSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 91. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 92. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 93. BRAZIL HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 103.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 104.ABBVIE INC.: OPERATING SEGMENTS
TABLE 105.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 106.ABBVIE INC.: NET SALES,
TABLE 107.ABBVIE INC.: KEY STRATERGIES
TABLE 108.AVANOR HEALTHCARE LTD: COMPANY SNAPSHOT
TABLE 109.AVANOR HEALTHCARE LTD: OPERATING SEGMENTS
TABLE 110.AVANOR HEALTHCARE LTD: PRODUCT PORTFOLIO
TABLE 111.AVANOR HEALTHCARE LTD: NET SALES,
TABLE 112.AVANOR HEALTHCARE LTD: KEY STRATERGIES
TABLE 113.BRICKBELL BIOTECH, INC: COMPANY SNAPSHOT
TABLE 114.BRICKBELL BIOTECH, INC: OPERATING SEGMENTS
TABLE 115.BRICKBELL BIOTECH, INC: PRODUCT PORTFOLIO
TABLE 116.BRICKBELL BIOTECH, INC: NET SALES,
TABLE 117.BRICKBELL BIOTECH, INC: KEY STRATERGIES
TABLE 118.DR AUGUST WOLFF GMBH & CO. KG DRUGS: COMPANY SNAPSHOT
TABLE 119.DR AUGUST WOLFF GMBH & CO. KG DRUGS: OPERATING SEGMENTS
TABLE 120.DR AUGUST WOLFF GMBH & CO. KG DRUGS: PRODUCT PORTFOLIO
TABLE 121.DR AUGUST WOLFF GMBH & CO. KG DRUGS: NET SALES,
TABLE 122.DR AUGUST WOLFF GMBH & CO. KG DRUGS: KEY STRATERGIES
TABLE 123.EIRION THERAPEUTICS, INC: COMPANY SNAPSHOT
TABLE 124.EIRION THERAPEUTICS, INC: OPERATING SEGMENTS
TABLE 125.EIRION THERAPEUTICS, INC: PRODUCT PORTFOLIO
TABLE 126.EIRION THERAPEUTICS, INC: NET SALES,
TABLE 127.EIRION THERAPEUTICS, INC: KEY STRATERGIES
TABLE 128.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 129.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 130.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 131.ELI LILLY AND COMPANY: NET SALES,
TABLE 132.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 133.HUGEL, INC: COMPANY SNAPSHOT
TABLE 134.HUGEL, INC: OPERATING SEGMENTS
TABLE 135.HUGEL, INC: PRODUCT PORTFOLIO
TABLE 136.HUGEL, INC: NET SALES,
TABLE 137.HUGEL, INC: KEY STRATERGIES
TABLE 138.KAKEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 139.KAKEN PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 140.KAKEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 141.KAKEN PHARMACEUTICAL CO., LTD.: NET SALES,
TABLE 142.KAKEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
TABLE 143.ROIVANT SCIENCES LTD.: COMPANY SNAPSHOT
TABLE 144.ROIVANT SCIENCES LTD.: OPERATING SEGMENTS
TABLE 145.ROIVANT SCIENCES LTD.: PRODUCT PORTFOLIO
TABLE 146.ROIVANT SCIENCES LTD.: NET SALES,
TABLE 147.ROIVANT SCIENCES LTD.: KEY STRATERGIES
TABLE 148.THERAVIDA, INC: COMPANY SNAPSHOT
TABLE 149.THERAVIDA, INC: OPERATING SEGMENTS
TABLE 150.THERAVIDA, INC: PRODUCT PORTFOLIO
TABLE 151.THERAVIDA, INC: NET SALES,
TABLE 152.THERAVIDA, INC: KEY STRATERGIES
TABLE 153.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 154.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 155.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 156.DR. REDDY'S LABORATORIES LTD.: NET SALES,
TABLE 157.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
TABLE 158.INTAS PHARMACEUTICALS LTD: COMPANY SNAPSHOT
TABLE 159.INTAS PHARMACEUTICALS LTD: OPERATING SEGMENTS
TABLE 160.INTAS PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 161.INTAS PHARMACEUTICALS LTD: NET SALES,
TABLE 162.INTAS PHARMACEUTICALS LTD: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.HYPERHIDROSIS TREATMENT MARKET SEGMENTATION
FIGURE 2.HYPERHIDROSIS TREATMENT MARKET,2021-2031
FIGURE 3.HYPERHIDROSIS TREATMENT MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.HYPERHIDROSIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.PATENT ANALYSIS BY COMPANY
FIGURE 13.PATENT ANALYSIS BY COUNTRY
FIGURE 14.HYPERHIDROSIS TREATMENT MARKET,BY TYPE,2021(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF AXILLARY HYPERHIDROSIS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PALMAR HYPERHIDROSIS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PLANTAR HYPERHIDROSIS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 19.HYPERHIDROSIS TREATMENT MARKET,BY TREATMENT,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BOTULINUM TOXIN INJECTIONS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TOPICAL TREATMENT HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ORAL MEDICATION HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 23.HYPERHIDROSIS TREATMENT MARKET,BY AGE,2021(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF BELOW 50 YEARS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ABOVE 50 YEARS HYPERHIDROSIS TREATMENT MARKET,2021-2031(%)
FIGURE 26.HYPERHIDROSIS TREATMENT MARKET BY REGION,2021
FIGURE 27.U.S. HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 28.CANADA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 29.MEXICO HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 30.GERMANY HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 31.FRANCE HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 32.UK HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 33.ITALY HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 34.SPAIN HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 35.REST OF EUROPE HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 36.JAPAN HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 37.CHINA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 38.INDIA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 39.AUSTRALIA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 40.SOUTH KOREA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 41.REST OF ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 42.BRAZIL HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 43.SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 44.SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 45.REST OF LAMEA HYPERHIDROSIS TREATMENT MARKET,2021-2031($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50.COMPETITIVE DASHBOARD
FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 52.ABBVIE INC..: NET SALES ,($MILLION)
FIGURE 53.AVANOR HEALTHCARE LTD.: NET SALES ,($MILLION)
FIGURE 54.BRICKBELL BIOTECH, INC.: NET SALES ,($MILLION)
FIGURE 55.DR AUGUST WOLFF GMBH & CO. KG DRUGS.: NET SALES ,($MILLION)
FIGURE 56.EIRION THERAPEUTICS, INC.: NET SALES ,($MILLION)
FIGURE 57.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 58.HUGEL, INC.: NET SALES ,($MILLION)
FIGURE 59.KAKEN PHARMACEUTICAL CO., LTD..: NET SALES ,($MILLION)
FIGURE 60.ROIVANT SCIENCES LTD..: NET SALES ,($MILLION)
FIGURE 61.THERAVIDA, INC.: NET SALES ,($MILLION)
FIGURE 62.DR. REDDY'S LABORATORIES LTD..: NET SALES ,($MILLION)
FIGURE 63.INTAS PHARMACEUTICALS LTD.: NET SALES ,($MILLION)

Product Code: A17523

The global hyperhidrosis treatment market was valued at $575.3 million in 2021, and is estimated to reach $ 950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031.

A person with hyperhidrosis experiences excessive and unpredictable sweating. When cool or when they are at rest, people with hyperhidrosis may nevertheless perspire. A person's body's sweat glands overreact in hyperhidrosis. Excessive sweating can occasionally be brought on by a health issue or emotion (such as anxiety). Controlling the symptoms of hyperhidrosis can be a constant struggle for many people. Hyperhidrosis patients seem to have excessively active sweat glands. Uncontrollable sweating can cause severe physical and emotional distress. The cause of hyperhidrosis is unidentified and it is generally believed to be the result of a disturbance with the portion of the nervous system that regulates sweating. The impact of hyperhidrosis symptoms on life can vary greatly in terms of their severity.

The major factors that drive the growth of the hyperhidrosis treatment market are rise in incidence of hyperhidrosis and surge in product launch & product approval are the factors attributed to the growth of the hyperhidrosis treatment market. In addition, upsurge in utilization of topical treatments is a key trend of the market, which is expected to fuel the market growth during the forecast period.Significant surge in the incidence of hyperhidrosis is one leading factor for the growth of the market. Estimates suggest between 2% and 5% of people in the U.S. have hyperhidrosis Thus, such high number of cases are expected to boost the hyperhidrosis treatment procedures.

In addition, rise in product launch drives the market growth, for instance, in June 2022, Dr August Wolff GmbH & Co. Kg Drugs presented the new drug Axhidrox. It is topical treatment for severe primary axillary hyperhidrosis in adults. However, lack of awareness about treatment scenario is expected to hinder the growth of the market. Conversely, increasing consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.

The hyperhidrosis treatment market is segmented on the basis of type, treatment, age, and region. On the basis of type, the market is categorized into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. By treatment, it is divided into botulinum toxin injection, topical treatment, and oral medication. Oral medication is further bifurcated into anticholinergics and others. By age, it is classified into below 50 years and above 50 years. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc, Avanor Healthcare Ltd , Brickbell Biotech, Inc , Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperhidrosis treatment market analysis from 2021 to 2031 to identify the prevailing hyperhidrosis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hyperhidrosis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hyperhidrosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Axillary hyperhidrosis
Palmar hyperhidrosis
Plantar hyperhidrosis
Others

By Treatment

Botulinum toxin injections
Topical treatment
Oral medication
- Type
- Anticholinergics
- Others

By Age

Below 50 years
Above 50 years

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- AbbVie Inc.
- Avanor Healthcare Ltd
- Brickbell Biotech, Inc
- Dr August Wolff Gmbh & Co. Kg Drugs
- Eirion Therapeutics, Inc
- Eli Lilly and Company
- Hugel, Inc
- Kaken Pharmaceutical Co., Ltd.
- Roivant Sciences Ltd.
- Theravida, Inc
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Ltd

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape

CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Axillary hyperhidrosis
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Palmar hyperhidrosis
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Plantar hyperhidrosis
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country

CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Botulinum toxin injections
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Topical treatment
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Oral medication
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.4.4 Oral medication Hyperhidrosis Treatment Market by Type
  - 5.4.4.1 Anticholinergics Market size and forecast, by region
  - 5.4.4.2 Others Market size and forecast, by region

CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Below 50 years
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Above 50 years
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country

CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Treatment
  - 7.2.3.1 North America Oral medication Hyperhidrosis Treatment Market by Type
- 7.2.4 North America Market size and forecast, by Age
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Type
  - 7.2.5.1.2 Market size and forecast, by Treatment
  - 7.2.5.1.3 Market size and forecast, by Age
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Type
  - 7.2.5.2.2 Market size and forecast, by Treatment
  - 7.2.5.2.3 Market size and forecast, by Age
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Type
  - 7.2.5.3.2 Market size and forecast, by Treatment
  - 7.2.5.3.3 Market size and forecast, by Age
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Treatment
  - 7.3.3.1 Europe Oral medication Hyperhidrosis Treatment Market by Type
- 7.3.4 Europe Market size and forecast, by Age
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Type
  - 7.3.5.1.2 Market size and forecast, by Treatment
  - 7.3.5.1.3 Market size and forecast, by Age
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Type
  - 7.3.5.2.2 Market size and forecast, by Treatment
  - 7.3.5.2.3 Market size and forecast, by Age
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Type
  - 7.3.5.3.2 Market size and forecast, by Treatment
  - 7.3.5.3.3 Market size and forecast, by Age
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Type
  - 7.3.5.4.2 Market size and forecast, by Treatment
  - 7.3.5.4.3 Market size and forecast, by Age
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Type
  - 7.3.5.5.2 Market size and forecast, by Treatment
  - 7.3.5.5.3 Market size and forecast, by Age
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Type
  - 7.3.5.6.2 Market size and forecast, by Treatment
  - 7.3.5.6.3 Market size and forecast, by Age
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
  - 7.4.3.1 Asia-Pacific Oral medication Hyperhidrosis Treatment Market by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Age
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Type
  - 7.4.5.1.2 Market size and forecast, by Treatment
  - 7.4.5.1.3 Market size and forecast, by Age
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Type
  - 7.4.5.2.2 Market size and forecast, by Treatment
  - 7.4.5.2.3 Market size and forecast, by Age
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Type
  - 7.4.5.3.2 Market size and forecast, by Treatment
  - 7.4.5.3.3 Market size and forecast, by Age
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Type
  - 7.4.5.4.2 Market size and forecast, by Treatment
  - 7.4.5.4.3 Market size and forecast, by Age
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Type
  - 7.4.5.5.2 Market size and forecast, by Treatment
  - 7.4.5.5.3 Market size and forecast, by Age
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Type
  - 7.4.5.6.2 Market size and forecast, by Treatment
  - 7.4.5.6.3 Market size and forecast, by Age
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
  - 7.5.3.1 LAMEA Oral medication Hyperhidrosis Treatment Market by Type
- 7.5.4 LAMEA Market size and forecast, by Age
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Type
  - 7.5.5.1.2 Market size and forecast, by Treatment
  - 7.5.5.1.3 Market size and forecast, by Age
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Type
  - 7.5.5.2.2 Market size and forecast, by Treatment
  - 7.5.5.2.3 Market size and forecast, by Age
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Type
  - 7.5.5.3.2 Market size and forecast, by Treatment
  - 7.5.5.3.3 Market size and forecast, by Age
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Type
  - 7.5.5.4.2 Market size and forecast, by Treatment
  - 7.5.5.4.3 Market size and forecast, by Age

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 AbbVie Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Avanor Healthcare Ltd
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Brickbell Biotech, Inc
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Dr August Wolff Gmbh & Co. Kg Drugs
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Eirion Therapeutics, Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Eli Lilly and Company
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Hugel, Inc
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Kaken Pharmaceutical Co., Ltd.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Roivant Sciences Ltd.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Theravida, Inc
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Dr. Reddy's Laboratories Ltd.
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Intas Pharmaceuticals Ltd
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments

多汗症治療市場：タイプ別、治療別、年齢別：世界の機会分析および産業予測、2021-2031年

Hyperhidrosis Treatment Market By Type, By Treatment, By Age : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章多汗症治療市場：タイプ別

第5章多汗症治療市場：治療別

第6章多汗症治療市場：年齢別

第7章多汗症治療市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE

CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT

CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE

CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

多汗症治療市場：タイプ別、治療別、年齢別：世界の機会分析および産業予測、2021-2031年

Hyperhidrosis Treatment Market By Type, By Treatment, By Age : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 多汗症治療市場：タイプ別

第5章 多汗症治療市場：治療別

第6章 多汗症治療市場：年齢別

第7章 多汗症治療市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE

CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT

CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE

CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章多汗症治療市場：タイプ別

第5章多汗症治療市場：治療別

第6章多汗症治療市場：年齢別

第7章多汗症治療市場：地域別

第8章企業情勢

第9章企業プロファイル